Agios Reports Second Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Agios Pharma (AGIO) PT Raised to $89 at Needham & Company
August 2, 2018 11:51 AM EDTNeedham & Company raised its price target on Agios Pharma (NASDAQ: AGIO) to $89.00 (from $86.00) while maintaining a Buy rating.
Analyst Chad Messer commented, "Both TIBSOVO and IDHIFA are now approved in relapsed/refractory AML. Agios is focused on moving both drugs into earlier... More
Agios Pharma (AGIO) Tops Q2 EPS by 36c
August 2, 2018 7:02 AM EDTAgios Pharma (NASDAQ: AGIO) reported Q2 EPS of ($1.19), $0.36 better than the analyst estimate of ($1.55). Revenue for the quarter came in at $40.41 million versus the consensus estimate of $11.28 million.
For earnings history and earnings-related data on Agios Pharma (AGIO) click here.
... More